Hosted by Timmerman Report · EN
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.